Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO GuidelineLarissa A. Korde, Dawn L. Hershman, Preeti Sudheendra et al.|Journal of Clinical Oncology|2021Cited by 991
Neoadjuvant T-DM1/pertuzumab and paclitaxel/trastuzumab/pertuzumab for HER2+ breast cancer in the adaptively randomized I-SPY2 trialAmy S. Clark, Laura J. Esserman, Christina Yau et al.|Nature Communications|2021Cited by 73
Ganitumab and metformin plus standard neoadjuvant therapy in stage 2/3 breast cancerDouglas Yee, Jane Perlmutter, Claudine Isaacs et al.|npj Breast Cancer|2021Cited by 29
Safety and efficacy of HSP90 inhibitor ganetespib for neoadjuvant treatment of stage II/III breast cancerJulie E. Lang, Laura J. Esserman, Andres Forero‐Torres et al.|npj Breast Cancer|2022Cited by 27
Neoadjuvant Trebananib plus Paclitaxel-based Chemotherapy for Stage II/III Breast Cancer in the Adaptively Randomized I-SPY2 Trial—Efficacy and Biomarker DiscoveryKathy S. Albain, Laura J. Esserman, Christina Yau et al.|Clinical Cancer Research|2023Cited by 20